119 related articles for article (PubMed ID: 22037208)
1. A few good genes: simple, biologically motivated signatures for cancer prognosis.
Gentles AJ; Alizadeh AA
Cell Cycle; 2011 Nov; 10(21):3615-6. PubMed ID: 22037208
[No Abstract] [Full Text] [Related]
2. Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment.
Alizadeh AA; Gentles AJ; Alencar AJ; Liu CL; Kohrt HE; Houot R; Goldstein MJ; Zhao S; Natkunam Y; Advani RH; Gascoyne RD; Briones J; Tibshirani RJ; Myklebust JH; Plevritis SK; Lossos IS; Levy R
Blood; 2011 Aug; 118(5):1350-8. PubMed ID: 21670469
[TBL] [Abstract][Full Text] [Related]
3. LIM domain only 2 protein expression, LMO2 germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era.
Cerhan JR; Natkunam Y; Morton LM; Maurer MJ; Asmann Y; Habermann TM; Vasef MA; Cozen W; Lynch CF; Allmer C; Slager SL; Lossos IS; Chanock SJ; Rothman N; Hartge P; Dogan A; Wang SS
Leuk Lymphoma; 2012 Jun; 53(6):1105-12. PubMed ID: 22066713
[TBL] [Abstract][Full Text] [Related]
4. Identification of a Patient Cohort with Relapsing Diffuse Large B-Cell Lymphoma with a Low International Prognostic Index in PET/CT Using a 2-Gene (LMO2/TNFRSF9) Scoring System.
Omidvar N; Tekin N; Conget P; Bruna F; Timar B; Gagyi E; Basak R; Auewarakul C; Sritana N; Cerci JJ; Dimamay MP; Gyorke T; Redondo F; Nair R; Gorospe C; Paez D; Fanti S; Ozdag H; Padua RA; Carr R
Acta Haematol; 2020; 143(6):600-602. PubMed ID: 32187599
[No Abstract] [Full Text] [Related]
5. High expression of LMO2 in Hodgkin, Burkitt and germinal center diffuse large B cell lymphomas.
Shams TM
J Egypt Natl Canc Inst; 2011 Dec; 23(4):147-53. PubMed ID: 22776842
[TBL] [Abstract][Full Text] [Related]
6. BCL6--regulated by AhR/ARNT and wild-type MEF2B--drives expression of germinal center markers MYBL1 and LMO2.
Ding J; Dirks WG; Ehrentraut S; Geffers R; MacLeod RA; Nagel S; Pommerenke C; Romani J; Scherr M; Vaas LA; Zaborski M; Drexler HG; Quentmeier H
Haematologica; 2015 Jun; 100(6):801-9. PubMed ID: 25769544
[TBL] [Abstract][Full Text] [Related]
7. Identification of LMO2 transcriptome and interactome in diffuse large B-cell lymphoma.
Cubedo E; Gentles AJ; Huang C; Natkunam Y; Bhatt S; Lu X; Jiang X; Romero-Camarero I; Freud A; Zhao S; Bacchi CE; Martínez-Climent JA; Sánchez-García I; Melnick A; Lossos IS
Blood; 2012 Jun; 119(23):5478-91. PubMed ID: 22517897
[TBL] [Abstract][Full Text] [Related]
8. Correlation Analysis Between the Expression of MEF2B, and Germinal Center and Nongerminal Center Markers in Diffuse Large B-Cell Lymphoma.
Salama A; Marcellino BK; Saad AG; Teruya-Feldstein J; Firpo-Betancourt A; Abulsayen HA; Grada Z; Hassan M; El Jamal SM
Appl Immunohistochem Mol Morphol; 2020 Aug; 28(7):e63-e64. PubMed ID: 31850910
[No Abstract] [Full Text] [Related]
9. [Regulation of E-cadherin promoter activity by LMO2 impact on the progression and metastasis of prostate cancer].
Peng X; Ye Z; Gao Y
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2013 Sep; 29(5):385-9. PubMed ID: 24386807
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of LIM domain only 2 (LMO2) in chronic myelogenous leukaemia.
Atay MH; Ozatli D; Kelkitli E; Yildiz L; Turgut M; Guler N; Toptas T
Histopathology; 2013 Aug; 63(2):293-4. PubMed ID: 23879574
[No Abstract] [Full Text] [Related]
11. LMO2-negative Expression Predicts the Presence of MYC Translocations in Aggressive B-Cell Lymphomas.
Colomo L; Vazquez I; Papaleo N; Espinet B; Ferrer A; Franco C; Comerma L; Hernandez S; Calvo X; Salar A; Climent F; Mate JL; Forcada P; Mozos A; Nonell L; Martinez A; Carrio A; Costa D; Dlouhy I; Salaverria I; Martin-Subero JI; Lopez-Guillermo A; Valera A; Campo E;
Am J Surg Pathol; 2017 Jul; 41(7):877-886. PubMed ID: 28288039
[TBL] [Abstract][Full Text] [Related]
12. LASP1 in Tumor and Tumor Microenvironment.
Hu Z; Wang X; Cui Y; Li C; Wang S
Curr Mol Med; 2017; 17(8):541-548. PubMed ID: 29473505
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients.
Culpin RE; Sieniawski M; Angus B; Menon GK; Proctor SJ; Milne P; McCabe K; Mainou-Fowler T
Histopathology; 2013 Dec; 63(6):788-801. PubMed ID: 24117687
[TBL] [Abstract][Full Text] [Related]
14. BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome.
Tibiletti MG; Martin V; Bernasconi B; Del Curto B; Pecciarini L; Uccella S; Pruneri G; Ponzoni M; Mazzucchelli L; Martinelli G; Ferreri AJ; Pinotti G; Assanelli A; Scandurra M; Doglioni C; Zucca E; Capella C; Bertoni F
Hum Pathol; 2009 May; 40(5):645-52. PubMed ID: 19144384
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous rearrangements of TAL1 and LMO2 in T-cell acute lymphoblastic leukemia.
Kim HK; Lim JH; Koh KN; Chi HS; Seo EJ
Int J Lab Hematol; 2014 Oct; 36(5):e69-70. PubMed ID: 24330618
[No Abstract] [Full Text] [Related]
16. Distinct Ldb1/NLI complexes orchestrate γ-globin repression and reactivation through ETO2 in human adult erythroid cells.
Kiefer CM; Lee J; Hou C; Dale RK; Lee YT; Meier ER; Miller JL; Dean A
Blood; 2011 Dec; 118(23):6200-8. PubMed ID: 22010104
[TBL] [Abstract][Full Text] [Related]
17. LMO2 attenuates tumor growth by targeting the Wnt signaling pathway in breast and colorectal cancer.
Liu Y; Huang D; Wang Z; Wu C; Zhang Z; Wang D; Li Z; Zhu T; Yang S; Sun W
Sci Rep; 2016 Oct; 6():36050. PubMed ID: 27779255
[TBL] [Abstract][Full Text] [Related]
18. LMO2 functional and transcriptional regulatory profiles in hematopoietic cells.
Wu C; Yuan M; Gao Y; Sun W
Leuk Res; 2018 Dec; 75():11-14. PubMed ID: 30419549
[No Abstract] [Full Text] [Related]
19. Ras suppressor-1 promotes apoptosis in breast cancer cells by inhibiting PINCH-1 and activating p53-upregulated-modulator of apoptosis (PUMA); verification from metastatic breast cancer human samples.
Giotopoulou N; Valiakou V; Papanikolaou V; Dubos S; Athanassiou E; Tsezou A; Zacharia LC; Gkretsi V
Clin Exp Metastasis; 2015 Mar; 32(3):255-65. PubMed ID: 25647720
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of the immunohistochemical subtypes and prognosis of primary diffuse large B cell lymphoma of the central nervous system].
Min M; Lin L; Bi CF; Wang XQ; Luo TY; Zhao S; Zhang WY; Liu WP
Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):110-6. PubMed ID: 22780928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
